This study supports the application of targeted molecular therapy in thyroid cancer as suggested in earlier studies, by demonstrating that targeting mutated BRAF leads to drastic, selective phenotype changes in thyroid cancer cells in culture [31,32]. This evidence concerns the gene BRAF and thyroid cancer.